Compare Incyte Corporation (INCY) vs Monolithic Power Systems Inc (MPWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Monolithic Power Systems Inc — how do they compare? Incyte Corporation trades at $120.59 (market cap $24.54B), while Monolithic Power Systems Inc trades at $1,439.31 (market cap $68.90B). The key difference: Monolithic Power Systems Inc is far larger — about 2.8× Incyte Corporation's market cap, and Monolithic Power Systems Inc pays a 0.57% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | MPWR | |
|---|---|---|
Market Cap | $24.54B | $68.90B |
Sector | Health | Utilities |
52-Week High | $129.93 | $1.69K |
52-Week Low | $81.61 | $820.74 |
Enterprise Value | $20.04B | $67.51B |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
MPWR is trading at $1,437.94, up 4.12% today, reflecting strong momentum after recent earnings beats. The stock shows a bullish technical trend with support at $1,386 and resistance at $1,425. Fundamentally, Q2 2026 revenue surged to $980.6M, driven by 164.3% growth in Enterprise Data, with net income margin expanding to 24.5%. Analyst sentiment is overwhelmingly positive, with 88% recommending Buy and a consensus price target of $1,870.
Outlook remains favorable given robust AI-driven demand and upward earnings revisions, but risks include high valuation multiples (P/E 85.55) and potential double-ordering concerns. The stock offers growth exposure but requires monitoring of execution and competitive pressures in the semiconductor sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Monolithic Power Systems Inc
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →
